Abstract: The present invention relates to chimeric antigen receptor cells targeting ROBO1, in particular, enhanced CAR-T cells and CAR-NK cells targeting ROBO1, and preparation and application thereof. The cells can stably expressing CAR elements, while secreting extracellular domain molecules expressing PD-1 protein or mutants thereof, and thus may block PD-11PD-L1 molecular interaction. It has been found through animal experiments that the cells have very good anti-tumor effects, and the above-mentioned cells can significantly reduce tumor recurrence and improve the survival rate compared with the conventional ROBO1-targeted CAR modified cells.
Type:
Grant
Filed:
December 2, 2019
Date of Patent:
July 11, 2023
Assignee:
Asclepius (Suzhou) Technology Company Group Co., Ltd.
Abstract: Described herein are peptides from secretory phospholipase A2-IB and antibodies that can be used to reduce the contribution of the gastrointestinal tract to inflammatory processes including systemic inflammatory responses. Specifically, antibodies that bind specifically a peptide from secretory phospholipase A2-IB prevent death in a mouse model of LPS-induced endotoxemia. The antibodies described herein are particularly useful to treat systemic inflammatory response syndromes, including sepsis.
Type:
Grant
Filed:
April 14, 2017
Date of Patent:
July 4, 2023
Assignee:
WISCONSIN ALUMNI RESEARCH FOUNDATION
Inventors:
Jordan Marshall Sand, Mark Eric Cook, Daniel Elmer Butz
Abstract: The present invention generally relates to antigen binding receptors capable of specific binding to mutated Fc domains with reduced Fc receptor binding and T cells expressing these antigen binding receptors. More precisely, the present invention relates to T cells, transfected/transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. Furthermore, the invention relates to a kit comprising the T cells of the invention and/or nucleic acid molecules, vectors expressing antigen binding receptors of the present invention and (a) tumor targeting antibody/antibodies comprising a mutated Fc domain.
Type:
Grant
Filed:
September 19, 2019
Date of Patent:
June 20, 2023
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Kay-Gunnar Stubenrauch, Ekkehard Moessner, Christian Klein, Diana Darowski
Abstract: Provided are antibodies that bind to: a sulfonated epitope of the protein Sclerostin, to Sclerostin portions comprising a sulfonated amino acid and to dimerized forms of Sclerostin. Further provided are compositions and peptides comprising a sulfonated epitope of sclerostin. Also provided by this invention are methods for production of such antibodies, both active and passive, and methods for identifying antibodies specific for sulfonation sites in Sclerostin and other antibodies which discriminate between sulfonated and unsulfonated forms of sclerostin. Physical and virtual screening processes are provided in this invention for identifying compounds which disrupt or inhibit sulfonation and the interaction between Sclerostin and binding partners. The antibodies and compositions of the present invention are useful in diagnostic and therapeutic applications directed to Sclerostin-related disorders.
Abstract: The disclosure provides for single chain variable fragments to oxidized phospholipid epitopes and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents for treating CAS.
Type:
Grant
Filed:
May 29, 2018
Date of Patent:
May 23, 2023
Assignee:
The Regents of the University of California
Inventors:
Joseph L. Witztum, Sotirios Tsimikas, Xuchu Que
Abstract: The present application provides a group of human immortalized B lymphocyte cell lines and use thereof, and specifically provides a combination of four closely related immortalized lymphocyte cell lines. The combination can be used as a reference substances for measuring the performance of a detection platform. When the four closely related immortalized lymphocyte cell lines are used as reference substances for epigenome, transcriptome, proteome, and metabolome, an intrinsic magnitude difference gradient can be formed to evaluate the sensitivity of histological detection.
Type:
Grant
Filed:
November 9, 2018
Date of Patent:
May 9, 2023
Assignee:
FUDAN UNIVERSITY
Inventors:
Leming Shi, Yuanting Zheng, Wanwan Hou, Bin Li, Xingdong Chen, Ying Yu, Jiucun Wang, Li Jin
Abstract: The disclosure provides antibody immune cell inhibitor fusion proteins comprising four polypeptide chains that form two antigen binding sites and at least two immune cell receptor binding sites that inhibit or diminish activation of an immune effector cell when bound to a target antigen. The disclosure also provides antibody immune cell inhibitor fusion proteins comprising two polypeptide chains that form one antigen binding site and at least one immune cell receptor binding site that inhibit or diminish activation of an immune effector cell when bound to a target antigen. The disclosure further provides pharmaceutical compositions and kits that comprise such antibody immune cell inhibitor fusion proteins, and methods of treatment using such proteins.
Abstract: Molecules, including antibodies and antigen-binding fragments thereof that specifically bind to a linker peptide, and methods of producing and using the described antibodies and antigen-binding fragments are presented herein. Also presented herein methods of generating antibodies that specifically bind to an immunorecessive epitope.
Type:
Grant
Filed:
February 15, 2022
Date of Patent:
May 2, 2023
Assignee:
Janssen Biotech, Inc.
Inventors:
Sanjaya Singh, Rajkumar Ganesan, Jun Chen, Iqbal S. Grewal
Abstract: Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. In one embodiment, the Wnt pathway protein is the Dickkopf1 (Dkk1) protein. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, such as a Dkk1, wherein the fragment is sulfated.
Abstract: This provides pharmaceutical compositions that comprise a combination of an anti-cancer agent which is an first antibody and a second antibody. In some embodiments, the first antibody is an anti-Programmed Death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed dose formulation. In certain embodiments, the composition is administered as a flat-dose. The disclosure also provides a kit for treating a subject afflicted with a disease, the kit comprising a dosage of any composition disclosed herein and instructions for using the composition in any of the disclosed methods for treating a disease.
Abstract: The present invention relates to compositions and methods of use of anti-ADAMTS13 autoantibodies and fragments thereof. In one aspect, the invention includes a composition comprising an isolated anti-ADAMTS13 autoantibody or fragment thereof. In other aspects, methods are described for generating an in vivo model of thrombotic thrombocytopenic purpura (TTP) comprising introducing at least one anti-ADAMTS13 autoantibody or fragment thereof into a model organism and identifying an anti-autoimmune reagent for treating TTP.
Type:
Grant
Filed:
April 6, 2016
Date of Patent:
March 7, 2023
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
Donald L. Siegel, Stephen Kacir, Eric Ostertag, X. Long Zheng
Abstract: Disclosed herein are antibodies against ENPP3 and uses thereof, specifically monoclonal antibodies against ENPP3, bispecific antibodies against ENPP3 and CD3, nucleic acids including nucleotide sequences encoding the antibodies, vectors including the nucleic acids, and host cell including the nucleic acids or the vectors. Also disclosed are pharmaceutical compositions and conjugates including the antibodies, and therapeutic methods for using the antibodies.
Abstract: The present invention provides binder directed to and binding to a DPP3 protein or functional derivative thereof and its use in a method of prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress. With this context, specifically the present invention provides a binder being directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three amino acids of SEQ ID NO.: 2.
Abstract: The present invention relates to an anti-MRS monoclonal antibody and, more specifically, to an antibody or a fragment thereof characterized by specifically binding to a fragment represented by amino acid 861-900 of a human-derived methionyl-tRNA synthetase (MRS) protein set forth in SEQ ID NO:1, a method for producing the same, and a composition for diagnosing cancer comprising the same. The antibody or the fragment thereof of the present invention specifically binds to the human-derived MRS, and has no cross-reactivity with other proteins comprising the same ARS family. Therefore, as MRS detection is possible, the antibody or a fragment thereof can be effectively used for diagnosing MRS-related cancer.
Abstract: Provided herein are antibodies capable of binding to YKL-40. These YKL-40 antibodies are suitable for multiple purposes, for example for detection of YKL-40.
Abstract: The present invention relates to the field of biotechnology and provides monoclonal tri-specific binding molecules that specifically bind to human IL-17A, human IL-17F, and a human pro-inflammatory molecule (in particular, TNF?) with high affinity. The invention also relates to DNA constructs encoding said binding molecules, related expression vectors and methods of production, and methods of treatment using said binding molecules.
Type:
Grant
Filed:
December 2, 2016
Date of Patent:
September 27, 2022
Inventors:
Dmitry Valentinovich Morozov, Andrei Borisovich Ulitin, Ekaterina Sergeevna Zubareva, Iakov Iurevich Ustiugov, Aleksandr Vladimirovich Karabelskii, Dmitry Valeryevich Korzhavin, Tatiana Veniaminovna Chernovskaya, Aleksandr Valerevich Grachev, Yury Ivanovich Basovskiy, Ekaterina Aleksandrovna Lomkova, Veronika Sergeevna Usatova, Aleksei Aleksandrovich Aleksandrov, Elena Leonidovna Morozova, Roman Alekseevich Ivanov, Pavel Andreevich Iakovlev
Abstract: Monoclonal antibodies directed to ceramide that inhibit apoptosis are disclosed. Humanized and scFv versions of the antibodies are also disclosed. Methods for prevention or treatment of apoptosis in a subject by administration of the anti-ceramide antibodies are disclosed.
Type:
Grant
Filed:
September 11, 2019
Date of Patent:
September 20, 2022
Assignees:
MEMORIAL SLOAN KETTERING CANCER CENTER, CERAMIDE THERAPEUTICS